TREATMENT OF KNEE OSTEOARTHRITIS WITH SM04690 IMPROVED WOMAC A1 'PAIN ON WALKING' RESULTS FROM A 52 WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF A NOVEL, INTRA-ARTICULAR, WNT PATHWAY INHIBITOR

被引：5
|
作者：
Kennedy, S. [1 ]
Ghandehari, H. [1 ]
Swearingen, C. [1 ]
Tambiah, J. [1 ]
Hochberg, M. [2 ]
机构：
[1] Samumed LLC, San Diego, CA USA
[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.5547
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0061
引用
收藏
页码：81 / 82
页数：2
相关论文
共 50 条
  • [21] A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study
    Yazici, Y.
    McAlindon, T. E.
    Fleischmann, R.
    Gibofsky, A.
    Lane, N. E.
    Kivitz, A. J.
    Skrepnik, N.
    Armas, E.
    Swearingen, C. J.
    DiFrancesco, A.
    Tambiah, J. R. S.
    Hood, J.
    Hochberg, M. C.
    OSTEOARTHRITIS AND CARTILAGE, 2017, 25 (10) : 1598 - 1606
  • [22] EFFECTS OF INTRA-ARTICULAR CLODRONATE IN THE TREATMENT OF KNEE OSTEOARTHRITIS: RESULTS OF A DOUBLE-BLIND, RANDOMISED PLACEBO-CONTROLLED TRIAL
    Orsolini, G.
    Idolazzi, L.
    Rossini, M.
    Viapiana, O.
    Fracassi, E.
    Povino, M.
    Risoli, M.
    Gatti, D.
    Adami, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 745 - 745
  • [23] PROSPECTIVE COMPARISON OF INTRA-ARTICULAR SHAM VS. PLACEBO INJECTIONS: DATA FROM A RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SM04690, A WNT PATHWAY INHIBITOR FOR KNEE OSTEOARTHRITIS
    Yazici, Y.
    Tambiah, J.
    Swearingen, C.
    Kennedy, S.
    Strand, V.
    Cole, B.
    Hochberg, M.
    Bannuru, R.
    McAlindon, T.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S519 - S520
  • [24] Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial
    Maurizio Rossini
    Silvano Adami
    Elena Fracassi
    Ombretta Viapiana
    Giovanni Orsolini
    Maria Rosaria Povino
    Luca Idolazzi
    Davide Gatti
    Rheumatology International, 2015, 35 : 255 - 263
  • [25] Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial
    Rossini, Maurizio
    Adami, Silvano
    Fracassi, Elena
    Viapiana, Ombretta
    Orsolini, Giovanni
    Povino, Maria Rosaria
    Idolazzi, Luca
    Gatti, Davide
    RHEUMATOLOGY INTERNATIONAL, 2015, 35 (02) : 255 - 263
  • [26] COMPARISON OF INTRA-ARTICULAR SHAM AND VEHICLE INJECTIONS FROM A PHASE 2B TRIAL OF SM04690, A SMALL-MOLECULE WNT PATHWAY INHIBITOR FOR KNEE OSTEOARTHRITIS
    Yazici, Yusuf
    Tambiah, Jeyanesh
    Swearingen, Christopher
    Kennedy, Sarah
    Strand, Vibeke
    Cole, Brian
    Hochberg, Marc
    Bannuru, Raveendhara
    Mcalindon, Timothy
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 494 - 494
  • [27] INTEGRATED SAFETY SUMMARY OF THE NOVEL, INTRA-ARTICULAR AGENT LORECIVIVINT (SM04690), A CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, IN SUBJECTS WITH KNEE OSTEOARTHRITIS
    Simsek, I.
    Swearingen, C.
    Kennedy, S.
    Tambiah, J.
    Damatarca, C.
    Yazici, Y.
    Lane, N.
    Hochberg, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 117 - 117
  • [28] INTEGRATED SAFETY SUMMARY OF THE NOVEL, INTRA-ARTICULAR AGENT LORECIVIVINT (SM04690), A CLK/DYRK1A INHIBITOR THAT MODULATES THE WNT PATHWAY, IN SUBJECTS WITH KNEE OSTEOARTHRITIS
    Kennedy, Sarah
    Simsek, Ismail
    Swearingen, Christopher J.
    Tambiah, Jeyanesh
    Damatarca, Cristina
    Yazici, Yusuf
    Lane, Nancy E.
    Hochberg, Marc C.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 121 - 121
  • [29] Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis
    Simsek, Ismail
    Swearingen, Chris
    Kennedy, Sarah
    Tambiah, Jeyanesh
    Yazici, Yusuf
    Lane, Nancy
    Hochberg, Marc C.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [30] THE NOVEL, INTRA-ARTICULAR CLK/DYRK1A INHIBITOR LORECIVIVINT (SM04690), A WNT PATHWAY MODULATOR, IMPROVED RESPONDER OUTCOMES IN SUBJECTS WITH KNEE OSTEOARTHRITIS: A POST HOC ANALYSIS FROM A PHASE 2B TRIAL
    Tambiah, J.
    Kennedy, S.
    Swearingen, C.
    Yazici, Y.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S45 - S46
12345